|Appearance||White Fine Powder|
|Grade||Medicine & feed|
|Shelf life||2 Years|
Pomalidomide is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.
1. Supply top quality products with a reasonable price.
2. Arrange the orders and shipping with your requests on time, According to the different countries export policy provide complete customs clearance documents.
3. Samples can be arranged for testing and Unconditional assume responds.
4. Provide a price trend, ensure the clients can know about marketing informations in time.
Perampanel is a selective noncompetitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Perampanel was found to be effective in the treatment of refractory partial-onset seizures in three pivotal (Phase 3) clinical trials and has been approved for marketing under the brand name Fycompa by the European Medicines Agency. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older. Perampanel is discontinued.
Packing and Shipping: